Adimab Revenue and Competitors

Claim your profile

Lebanon, NH USA

Location

$45.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Adimab's estimated annual revenue is currently $29.6M per year.(i)
  • Adimab received $25.0M in venture funding in April 2012.
  • Adimab's estimated revenue per employee is $193,750
  • Adimab's total funding is $45.5M.
  • Adimab's current valuation is $1B. (February 2015)

Employee Data

  • Adimab has 153 Employees.(i)
  • Adimab grew their employee count by 14% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$43108M219939N/AN/AN/A

Adimab's yeast-based discovery platform functions as a synthetic human immune system to create novel antibody therapeutics across an extensive range of diseases, including cancer as well as autoimmune and infectious diseases. We are a profitable privately-held biotech company, backed by top-tier venture capital firms including Google Ventures, OrbiMed Advisors, Polaris Partners, and SV Life Sciences. We are unique in our ability to take a long-term view on value creation which allows us to continuously refine and improve our technology and make substantial investments in R&D.

keywords:Biotechnology

$45.5M

Total Funding

153

Number of Employees

$29.6M

Revenue (est)

14%

Employee Growth %

$1B

Valuation

N/A

Accelerator

Adimab News

2022-03-30 - Adagio to seek FDA authorization for antibody to prevent and ...

Trisha Sackett worked on isolating antibodies at Adimab in Lebanon, N.H., in December. Waltham-based Adagio Therapeutics was spun out of...

2022-03-22 - Ligand Pharma turns to a SPAC to take antibody biz public ...

OmniAb notes that both AbCellera and Adimab do not disclose if the programs or partnerships reflected in these totals are ongoing or terminated...

2017-10-23 - With a pipeline from Gern­gross’ Adimab, Ar­sa­nis hunts a $58M IPO for an­ti­body de­vel­op­ment work

Af­ter burn­ing through slight­ly more than $81 mil­lion, a biotech co-found­ed by Adimab’s Till­man Gern­gross has pen­cilled in a $57.5 mil­lion raise from an IPO de­signed to get its mid-stage pneu­mo­nia fight­ing an­ti­body through Phase II and down the road to a po­ten­tial ap­proval. Til ...

2015-08-06 - Avitide nets $7.5M for its next-gen biologics manufacturing process

The technology was spun out from Dartmouth College in 2013, and is chaired by storied biotech businessman Tillman Gerngross of Adimab. The company uses affinity purification to develop what it says is a highly precise biologics manufacturing system – separating out impurities that were previous ...

2012-04-02 - Adimab Closes Series F Financing

Adimab, LLC, a Lebanon, NH-based company that discovers fully human antibodies, has closed an over-subscribed Series F financing of undisclosed amount. The additional funds were raised entirely from existing investors. The company intends to use the capital to pursue complementary opportunitie ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$34M1636%N/A
#2
$63.8M1683%N/A
#3
$18.8M1713%N/A
#4
$15M17217%N/A
#5
$34.3M1735%N/A

Adimab Funding

DateAmountRoundLead InvestorsReference
2008-03-26$UndisclosedBPolaris Venture Partners, SV Life SciencesArticle
2008-11-21$UndisclosedCOrbiMed Advisors, Borealis VenturesArticle
2009-10-02$UndisclosedDGoogle VenturesArticle
2012-04-04$25.0MFPolaris Venture Partners, Borealis VenturesArticle

Adimab Executives


NameTitle
Eric KraulandChief Scientific Officer
Guy MeterChief Business Officer
Ryan McGovernCFO
Guy Van MeterChief Business Officer
Tillman GerngrossCo-Founder and CEO
Mary SchiavoniChief Human Resources Officer
Max VasquezVP Computational Biology
Mary SchiavoniVice President, Human Resources